[
    [
        {
            "time": "",
            "original_text": "中泰证券维持康泰生物买入评级：老牌疫苗企业厚积薄发，在研产品陆续进入收获期",
            "features": {
                "keywords": [
                    "康泰生物",
                    "疫苗",
                    "买入评级",
                    "在研产品",
                    "收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券维持康泰生物买入评级：老牌疫苗企业厚积薄发，在研产品陆续进入收获期",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]